Schonfeld Strategic Advisors’s Humacyte HUMA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,481	Closed	-$178K	–	2100
2021 Q1	$178K	Buy	+16,481	New	+$180K	﹤0.01%	1545

Other funds holding HUMA

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Tudor Investment Corp

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Altium Capital Management New York $42M AUM

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Omni Partners US Irvine, California $1.95B AUM

Arena Capital Advisors Los Angeles, California $200M AUM 23.6% 1-Year Est. Return

Schonfeld Strategic Advisors's HUMA Position: Q2 2021 in Review

Schonfeld Strategic Advisors sold out of Humacyte (HUMA) in Q2 2021, closing a stake of 16,481 shares — an estimated $178K sold.

Schonfeld Strategic Advisors first reported a position in HUMA in Q1 2021 and held it in 1 quarter. The position peaked at $178K in Q1 2021. 28 funds tracked by Wall St. Rank hold HUMA as of Q2 2021.

Schonfeld Strategic Advisors reported no remaining Humacyte position as of Q2 2021 after selling out during the quarter.
Schonfeld Strategic Advisors sold 16,481 Humacyte shares in Q2 2021, an estimated $178K.
Schonfeld Strategic Advisors first reported a position in Humacyte in Q1 2021 and held it in 1 quarter.
Schonfeld Strategic Advisors's Humacyte position peaked at $178K in Q1 2021.
28 funds tracked by Wall St. Rank held Humacyte as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.